APA (7th ed.) Citation

Dong, B., Chen, L., Pang, Q., Jiang, O., Ge, H., Cheng, Y., . . . Chen, M. (2024). TQB2450 with or without anlotinib as maintenance treatment in subjects with locally advanced/unresectable non-small cell lung cancer that have not progressed after prior concurrent/sequential chemoradiotherapy (R-ALPS): Study protocol for a randomized, double-blind, placebo-controlled, multicenter phase III trial. Translational lung cancer research, 13(10), 2828-2837. https://doi.org/10.21037/tlcr-24-362

Chicago Style (17th ed.) Citation

Dong, Baiqiang, et al. "TQB2450 with or Without Anlotinib as Maintenance Treatment in Subjects with Locally Advanced/unresectable Non-small Cell Lung Cancer That Have Not Progressed After Prior Concurrent/sequential Chemoradiotherapy (R-ALPS): Study Protocol for a Randomized, Double-blind, Placebo-controlled, Multicenter Phase III Trial." Translational Lung Cancer Research 13, no. 10 (2024): 2828-2837. https://doi.org/10.21037/tlcr-24-362.

MLA (9th ed.) Citation

Dong, Baiqiang, et al. "TQB2450 with or Without Anlotinib as Maintenance Treatment in Subjects with Locally Advanced/unresectable Non-small Cell Lung Cancer That Have Not Progressed After Prior Concurrent/sequential Chemoradiotherapy (R-ALPS): Study Protocol for a Randomized, Double-blind, Placebo-controlled, Multicenter Phase III Trial." Translational Lung Cancer Research, vol. 13, no. 10, 2024, pp. 2828-2837, https://doi.org/10.21037/tlcr-24-362.